Advertisement

Journal of Bone and Mineral Metabolism

, Volume 14, Issue 2, pp 73–78 | Cite as

Effect of elcatonin on involutional osteoporosis

  • Hajime Orimo
  • Hirotoshi Morii
  • Tetsuo Inoue
  • Kichizo Yamamoto
  • Hiroshi Minaguchi
  • Yoshiaki Ishii
  • Kagehisa Murota
  • Etsuo Fujimaki
  • Ryo Watanabe
  • Seiko Harata
  • Hideo Honjo
  • Takuo Fujita
Original Articles

Abstract

A total of 127 patients with involutional osteoporosis were randomly divided into two groups. The elcatonin group consisted of 67 patients who received 20 units of elcatonin per week administered intramuscularly, together with 0.6g calcium lactate (100mg as calcium) given orally three times daily for 24 weeks. The other 60 patients were assigned to a control group receiving 0.6g calcium lactate orally three times daily. Forty patients were withdrawn from the study treatment or dropped out during the study. The other 87 patients (consisting of 45 in the elcatonin group, and 42 in the control group) were measured for lumbar vertebral bone mineral density (BMD) using dual-energy X-ray absorptiometry (DXA). The BMD was increased significantly (P < 0.05) by 1.87 ± 0.79% (mean ± standard error) in the elcatonin group and decreased by 0.61 ± 0.93% in the control group at the end of the study. The difference between the two groups was statistically significant (P < 0.05). The results of the present study demonstrated that elcatonin increases the BMD in patients with involutional osteoporosis.

Key words

calcitonin-elcatonin DXA bone mineral density osteoporosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chesnutt III CH, Baylink DJ, Roos BA, Gruber HE, Ivey JL, Matthews M, Nelp WB (1981) Calcitonin and postmenopausal osteoporosis. In: Pecile A (ed) Calcitonin 1980. Excerpta Medica, Amsterdam, pp 247–255Google Scholar
  2. 2.
    Mazzuoli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin GF, Gonnelli S, Francini G (1986) Effect of salmon calcitonin in postmenopausal osteoporosis. Calcif Tissue Int 38:3–8PubMedGoogle Scholar
  3. 3.
    MacIntyre I, Stevenson JC, Whitehead MI, Wimalawansa SJ. Banks LM, Healy MJR (1988) Calcitonin for prevention of postmenopausal bone loss. Lancet 23: 900–901Google Scholar
  4. 4.
    Gennari C, Chierichetti SM, Bigazzi S, Fusi L, Gonneli S, Ferrara R, Zacchei F (1985) Comparative effects on BMD of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 38:455–464Google Scholar
  5. 5.
    Civitelli R, Gonneli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari G (1988) Bone turnover in postmenopausal osteoporosis; Effect of calcitonin treatment. J Clin Invest 82:1268–1274PubMedGoogle Scholar
  6. 6.
    Gruber HE, Ivy JL, Baylink DJ, Matthews M, Nelp WB, Sison K, Chesnutt III CH (1984) Long term calcitonin therapy in postmenopausal osteopororosis. Metabolism 33:295–303PubMedGoogle Scholar
  7. 7.
    Vigo P, Colombo B, Verdoia C, Girardello R, Ortolani S, Favini P, Corghi E, Polli EE (1981) Recent progress in the treatment of postmenopausal and senile osteoporosis. In: Pecile A (ed) Calcitonin 1980. Excerpta Medica, Amsterdam, pp 256–268Google Scholar
  8. 8.
    Morikawa T, Munakata E, Sakakibara S, Noda T, Otani M (1976) Synthesis of eel-calcitonin and [Asu1,7]-eel-calcitonin: Contribution of the disulfide bond to the hormone activity. Experientia 32:1104–1106PubMedGoogle Scholar
  9. 9.
    Otani M, Kitazawa S, Yamauchi H, Noda T, Watanabe S (1978) Biological activity of [Asu1,7]-eel-calcitonin (in Japanese). Clin Med 20:2217–2222Google Scholar
  10. 10.
    Orimo H (1990) The development of a novel therapy for bone disease, the discovery of elcatonin. In: Christiansen C, Overgard K (eds) Osteoporosis 1990. Handelstrykkeriet, Aalborg, pp 2091–2095Google Scholar
  11. 11.
    Yamamoto I, Morita R, Fukunaga M, Dokoh S, Shigeno C, Torizuka K, Noda T (1981) Adenylate cyclase activation and competitive binding with renal tissue using synthetic eel calcitonin analog and its fragments. Endocrinology 108:698–702PubMedGoogle Scholar
  12. 12.
    Hayashi T, Yamamoto T, Okumura H, Kasai R, Tada K (1989) Effect of [Asu1,7]-eel-calcitonin on the prevention of osteoporosis induced by combination of immobilization and ovariectomy in the rat. Bone 10:25–28PubMedGoogle Scholar
  13. 13.
    Nakatsuka K, Nishizawa Y, Hagiwara S, Koyama H, Miki T, Ochi H, Morii H (1990) Effect of calcitonin on total body bone mineral contents of experimental osteoporotic rats determined by dual photon absorptiometry. Calcif Tissue Int 47:378–382PubMedGoogle Scholar
  14. 14.
    Hori M, Takahashi H, Konno T, Inoue J, Haba T, Sakurada T, Noda T, Fujimoto K (1984) Effect of elcatonin on experimental models for osteoporosis due to ovariectomy and low-calcium diet in dogs (in Japanese with English abstract). Folia Pharmacol Jpn 84:91–98Google Scholar
  15. 15.
    Fujita T, Inoue T, Orimo H, Takahashi H, Morita R, Yamamuro T, Yamamoto K, Yoshikawa S (1990) Effect of elcatonin in osteoporosis: A multicenter, double-blind, placebo-controlled study (in Japanese). Igaku no Ayumi (J Clin Exper Med) 152:261–282Google Scholar
  16. 16.
    Fujita T, Inoue T, Orimo H, Takahashi H, Morita R, Yamamuro T, Yamamoto K, Yoshikawa S, Shimizu N (1989) Low dose intermittent calcitonin in therapy. J Bone Miner Res 179:4sGoogle Scholar
  17. 17.
    Inoue T, Kushida K, Miyamoto S, Sumi Y, Orimo H, Yamashita G (1983) Quantitative assessment of bone density on X-ray picture. J Jpn Orthop Assoc 57:1923–1926Google Scholar
  18. 18.
    Orimo H (1992) Criteria for the diagnosis of involutional osteoporosis. Asian Med J 35: 218–220Google Scholar
  19. 19.
    Farley JR, Tarbaux NM, Hall SL, Linkhart TA, Baylink DJ (1988) The anti-bone resorptive agent, calcitonin, also acts in vitro to directly increase bone formation and bone cell proliferation. Endocrinology 123:159–167PubMedGoogle Scholar
  20. 20.
    Hori M, Takahashi H, Konno T, Inoue J, Haba T, Noda T, Fujimoto K (1984) Effect of long-term administration of elcatonin on bone remodelling in dogs (in Japanese). Oyo Yakuri (Pharmacometrics) 28:609–614Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • Hajime Orimo
    • 1
  • Hirotoshi Morii
    • 2
  • Tetsuo Inoue
    • 3
  • Kichizo Yamamoto
    • 4
  • Hiroshi Minaguchi
    • 5
  • Yoshiaki Ishii
    • 6
  • Kagehisa Murota
    • 7
  • Etsuo Fujimaki
    • 8
  • Ryo Watanabe
    • 9
  • Seiko Harata
    • 10
  • Hideo Honjo
    • 11
  • Takuo Fujita
    • 12
  1. 1.Department of GeriatricsUniversity of Tokyo School of MedicineTokyoJapan
  2. 2.Second Department of Internal MedicineOsaka City University School of MedicineOsakaJapan
  3. 3.Department of Orthopedic SurgeryHamamatsu University School of MedicineShizuokaJapan
  4. 4.Department of Orthopedic SurgeryTottori University School of MedicineTottoriJapan
  5. 5.Department of Obstetrics and GynecologyYokohama City University School of MedicineYokohamaJapan
  6. 6.Department of Orthopedic SurgeryKyorin University School of MedicineTokyoJapan
  7. 7.Department of Orthopedic SurgeryJikei University School of MedicineTokyoJapan
  8. 8.Department of Orthopedic SurgeryShowa University School of MedicineTokyoJapan
  9. 9.Department of Orthopedic SurgeryKawasaki Medical SchoolOkayamaJapan
  10. 10.Department of Orthopedic SurgeryHirosaki University School of MedicineAomoriJapan
  11. 11.Department of Obstetrics and GynecologyKyoto Prefectural University School of MedicineKyotoJapan
  12. 12.Third Department of Internal MedicineKobe University School of MedicineHyogoJapan

Personalised recommendations